Your prediction
Pros and Cons of Merrimack Pharmaceuticals Inc. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
C******** o* t** e**********
Cons
?
S********** s********
?
B****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Merrimack Pharmaceuticals Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Merrimack Pharmaceuticals Inc. | - | - | - | - | - | - | - |
| Biocryst Pharmaceuticals | 5.090% | 6.313% | 2.126% | -32.317% | -10.616% | -38.465% | -33.785% |
| Heron Therapeutics Inc. | 4.990% | -6.716% | -21.875% | -40.898% | -10.233% | -59.283% | -93.483% |
| Madrigal Pharmaceuticals inc. | 0.050% | 2.136% | -4.924% | 29.543% | -17.492% | 44.824% | 307.026% |
Comments
Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Show more
Ratings data for MACK provided by MarketBeat
Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Show more
Ratings data for MACK provided by MarketBeat
